APA (7th ed.) Citation

F, Z., J, Z., D, Z., G, R., L, Q., T, W., . . . H, L. (2026). Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China. Cancer control : journal of the Moffitt Cancer Center, 33, 10732748261419187. https://doi.org/10.1177/10732748261419187

Chicago Style (17th ed.) Citation

F, Zheng, et al. "Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China." Cancer Control : Journal of the Moffitt Cancer Center 33 (2026): 10732748261419187. https://doi.org/10.1177/10732748261419187.

MLA (9th ed.) Citation

F, Zheng, et al. "Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China." Cancer Control : Journal of the Moffitt Cancer Center, vol. 33, 2026, p. 10732748261419187, https://doi.org/10.1177/10732748261419187.